glp 1 and cancer risk Glucagon-like peptide receptor agonists risk: the good, the bad and the unknown GLP-1 receptor agonists show anti-cancer
Description
The idea behind microdosing is pretty simple: you may not need the highest dose to make meaningful progress
10.2337/diabetes.53.5.1326 44
This work was supported by National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health grants DK021397 (to M.R.H.) and DK112812 (to B.C.D.J.) and Swiss National Science Foundation (SNSF) grant P400PB_186728 (to T.B.)
doi: 10.1007/s00125-024-06243-z
